Archies Limited has announced that its Board of Directors will convene on February 11, 2026 at 1:00 PM to consider and approve the unaudited financial results for the quarter ended December 31, 2025. The meeting notice was issued on February 5, 2026 in compliance with Regulation 29 and 47(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting will be held at the company's registered office to review the third quarter financial performance for FY26. Stakeholders can access related information on the company's investor website at www.archiesinvestors.in and on stock exchange websites including www.bseindia.com and www.nseindia.com .

Other Corporate Announcements

Several other companies also made significant announcements during this period. Inventurus Knowledge Solutions Limited published its unaudited financial results for the quarter and nine months ended December 31, 2025. The company demonstrated strong performance with consolidated revenue from operations reaching ₹8,149.50 million for Q3FY25 compared to ₹6,571.61 million in Q3FY24.

Inventurus Knowledge Solutions Performance

Astral Limited also approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 5, 2026 based on Audit Committee recommendations.

Regulatory Compliance

All companies have ensured compliance with SEBI regulations by publishing their results on respective company websites and stock exchange platforms. The financial results are available with statutory auditor reports and can be accessed through QR codes provided in the official announcements.

Investors and stakeholders are advised to refer to the complete financial statements available on company websites and stock exchange portals for detailed analysis of the quarterly performance.

Inventurus Knowledge Solutions Limited has announced strong financial results for Q3FY26, demonstrating significant growth across key performance metrics with substantial EBITDA improvements and strategic business expansion. The technology-enabled healthcare solutions provider reported robust quarterly performance ended December 31, 2025.

Financial Performance Overview

The company delivered impressive consolidated results for Q3FY26, with substantial improvements across revenue, profitability, and operational efficiency metrics compared to the previous year.

Strategic Business Expansion

IKS Health continues to expand its reach through strategic partnerships that enhance financial performance and improve clinical efficiency for healthcare providers. Key business highlights include new partnerships with StrideCare, a Texas-based multi-specialty physician group, and expanded collaboration with VitalMD Group Holding encompassing ambient solutions from the Scribble Suite. The company also strengthened its partnership with a top 5 health system to include additional regions and states within RCM and Value-Based Care services.

Nine-Month Performance

For the nine months ended December 31, 2025, the consolidated performance showed consistent growth momentum across all major financial parameters.

Regulatory Filing and Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has filed its investor presentation on Q3FY26 financial results with BSE Limited and National Stock Exchange of India Limited. The presentation is also available on the company's website at ikshealth.com/investor-relations. Company Secretary and Compliance Officer Sameer Chavan signed the regulatory filing dated February 4, 2026.

Leadership Commentary and Market Position

Sachin K. Gupta, Founder & Global CEO, highlighted that the strong Q3 performance validates their Care Enablement Platform as a critical solution for the US healthcare market facing cost, quality, and access pressures. The company continues advancing AI capabilities, specifically moving Patient Engagement suite toward multi-agent orchestration for cognitive reasoning and independent action. Group CFO Nithya Balasubramanian emphasized that margin expansion results from successful operating leverage, technology deployment, and focused cost management.

Recognition and Awards

The company received significant industry recognition, winning a 2026 Best in KLAS Award for Virtual Scribing Services for the second consecutive year. Additionally, CEO Sachin K. Gupta won the ET Edge Impactful CEO Award in the Large Enterprise category, demonstrating the company's leadership position in healthcare technology solutions.